NeuroPace at AAN 2025

Skip to main content
NeuroPace, Inc
  • Patients
  • Providers
  • Corporate
  • Investors
  • nSight
  • PDMS
  • Take the Quiz
  • Clinical Trials
  • Learn About the RNS System
    • Drug-Resistant Epilepsy
    • The RNS System
  • See if you Qualify
    • Take the Quiz
    • Find a Center
  • Preliminary NAUTILUS Results
  • Hear from Patients
    • Patient Stories
    • How Data Helped
    • RNS Community Chat
  • Resources
    • Find a Center
    • RNS Community Chat
    • Education (brochures, infographics, videos)
    • Helpful Links
    • Clinical Trials
    • Contact Us
  • Blog
  • Current Patients
    • Manuals
    • MRI Safety
    • How-to Videos
    • Living with the RNS System
    • Current Patient FAQ
  • Learn About the RNS System
    • Drug-Resistant Epilepsy
    • The RNS System
  • See if you Qualify
    • Take the Quiz
    • Find a Center
  • Preliminary NAUTILUS Results
  • Hear from Patients
    • Patient Stories
    • How Data Helped
    • RNS Community Chat
  • Resources
    • Find a Center
    • RNS Community Chat
    • Education (brochures, infographics, videos)
    • Helpful Links
    • Clinical Trials
    • Contact Us
  • Blog
  • Current Patients
    • Manuals
    • MRI Safety
    • How-to Videos
    • Living with the RNS System
    • Current Patient FAQ
Press enter to begin your search

NeuroPace at AAN 2025

Conclusive Evidence. Lasting Impact.

Groundbreaking 3-Year Data on the RNS® System

See the results of the RNS System Post-Approval Study at AAN 2025:

  • Three-year clinical data on brain-responsive stimulation
  • Prospective, FDA-reviewed trial with 324 patients
  • Key implications for treatment of drug-resistant focal epilepsy

Preview Abstract

RNS System Post-Approval Study Presentations

SESSION S20:

Multicenter Post-Approval Study of the RNS System in Focal Epilepsy

  • Monday, April 7, 5:06 PM PT
  • San Diego Convention Center | 29A

Oral abstract presentation of the 3-year RNS System Post-Approval Study Results in adults with drug-resistant focal epilepsy.

Add to Calendar Preview Abstract
Dawn Eliashiv, MD
Featured Speaker:
Dawn Eliashiv, MD
UCLA

EXHIBITOR PRESENTATION STAGE

Unmatched Outcomes:
Results of the RNS System Post-Approval Study for Drug-Resistant Focal Epilepsy

  • Tuesday, April 8, at 12:00 PM PT
  • AAN Exhibit Hall Presentation Stage

The presentation will provide 3-year study results from the RNS Post-Approval Study and discuss the reasons why outcomes are improved from earlier studies.

Add to Calendar Preview Abstract
Featured Speakers:
Martha Morrell, MD
Martha Morrell, MD
CMO, NeuroPace
Barbara C. Jobst, MD
Barbara C. Jobst, MD
Dartmouth

Unable to Attend AAN?

Join this exclusive webinar to see the latest clinical evidence.

Encore Webinar

Unmatched Outcomes:
Results of the RNS System Post-Approval Study for Drug-Resistant Focal Epilepsy

  • Tuesday, April 8, 8:00 AM PT
  • OR
  • Friday, April 11, 12:00 PM PT

Dawn Eliashiv, MD and Martha Morrell, MD will share insights from AAN in this live webinar.

Register Here

Visit Booth #1642 at AAN 2025

Discuss the key findings and their impact on treatment for drug-resistant focal epilepsy—because the future of neuromodulation starts here.

Get the latest updates about scientific publications, product announcements, and educational programs offered by NeuroPace.

Sign up for our newsletter 

Rx Only. The RNS® System is an adjunctive therapy for adults with refractory, partial onset seizures with no more than 2 epileptogenic foci. See important prescribing and safety information at www.NeuroPace.com/safety. Refer to the labeling for a description of the RNS® System and its components, indications for use, contraindications, warnings, cautions, adverse events and instructions for use.
©2025 NeuroPace, Inc. NeuroPace, the NeuroPace logo, and RNS are registered trademarks of NeuroPace, Inc. Mountain View, CA 94043.
NP250021 Rev1 Date 2025-03

  • Safety Information
  • Legal
  • Privacy Policy
1-866-726-387624-hr Support Line

PATIENTS

  • Drug-Resistant Epilepsy
  • The RNS System
  • Hear from Patients
  • Is It Right for You?
  • Current Patients
  • Resources

PROVIDERS

  • Product
  • Clinical Benefits
  • Actionable Insights
  • Patient Selection
  • Education & Training
  • Resources

CORPORATE

  • In The News
  • Press Releases
  • Leadership
  • Careers
  • Contact Us
  • FCOI Procedure

  • PATIENTS

    Safety

  • PROVIDERS

    Legal

  • INVESTORS

    Privacy Policy

  • CORPORATE

1-866-726-3876 24-hr Support Line

© 2026 NeuroPace, Inc.

Step 1 of 7

14%
    The RNS System is for individuals 18 and older who have focal epilepsy and have tried two or more medications without finding seizure control.

  • Based on your answers, your patient might benefit from the RNS System.

    Get your profile and a list of questions to ask your doctor.

  • Unfortunately it appears your patient is not an appropriate candidate for the RNS® System at this time.

  • The RNS® System is intended for patients who have undergone diagnostic testing that localized no more than 2 epileptogenic foci.

    If your patient has not undergone diagnostic testing, search here to find a comprehensive epilepsy center that can evaluate your patient, including determining if the RNS System is right for them.

  • If you are interested in learning more about the RNS® System, you can have an RNS® System professional contact you by filling out the form below:

  • By filling out this form, you are agreeing to the terms of our privacy policy. This form is intended for US residents only.

    By clicking submit, you are agreeing to receive communications from NeuroPace. You can unsubscribe at any time.

    * Required fileds

Share your Story: Terms and conditions

By filling out the form and submitting your story (and/or photograph), you are agreeing to the following:

  1. NeuroPace may review the information and any photographs you provide for potential publication on our website.
  2. If NeuroPace decides to use your story, we will contact you and ask you to sign a release for a version of your story to be used on the NeuroPace website, Facebook, Instagram, Twitter and/or LinkedIn. Unless you sign the release, we will not publish the story, your name, or the photographs you provided.
  3. Regardless of whether we publish your story, we will add your name and e-mail address to the NeuroPace email list to hear from us about product updates, upcoming events and other relevant information. We will not sell your information to third parties. 
  4. Our use of your information is subject to our Privacy Policy, which you can access here.
neuropace logoLogo Header Menu
  • Patients
  • Providers
  • Corporate
  • Investors
  • nSight
  • PDMS
  • Take the Quiz
  • Clinical Trials